Generate Biomedicines director gets 29,561-share option

Fanucci Marsha reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Fanucci Marsha reported acquisition or exercise transactions in this Form 4 filing.

Generate Biomedicines, Inc. director Marsha Fanucci reported receiving a stock option grant for 29,561 shares on February 26, 2026. The option has a price per share of $0.00, reflecting a compensatory award rather than an open-market purchase. These option shares vest in full on February 19, 2027, if she continues in service through that date.

Insights

Equity Compensation Analyst

Director receives standard equity option grant vesting in 2027.

Director Marsha Fanucci acquired a stock option for 29,561 shares of Generate Biomedicines, Inc. at an exercise price of $0.00 per share. The transaction is coded as a grant or award, indicating routine equity-based compensation rather than a market trade.

The option vests in full on February 19, 2027, conditioned on her continued service. This type of time-based vesting is designed to align director incentives with longer-term company performance. As a single award with no sale activity reported, it is a neutral development for existing shareholders.

Insider Trade Summary

Grant/Award: 29,561 shares

Grant/Award 1 txn

Insider Fanucci Marsha

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	29,561	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 29,561 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Generate Biomedicines (GENB) report for Marsha Fanucci?

Generate Biomedicines reported that director Marsha Fanucci received a stock option grant for 29,561 shares. The option was awarded on February 26, 2026 as a compensatory grant, rather than an open-market purchase or sale of existing shares.

Was the GENB insider Form 4 transaction a stock purchase or sale?

The Form 4 for Generate Biomedicines (GENB) shows an option grant, not a stock purchase or sale. Director Marsha Fanucci acquired a derivative security (stock option) as a grant/award acquisition, with no reported open-market buying or selling activity.

How many shares are covered by Marsha Fanucci’s Generate Biomedicines stock option?

The reported stock option grant to Marsha Fanucci covers 29,561 shares of Generate Biomedicines common stock. Following this transaction, the Form 4 indicates she held 29,561 option shares related to this award as a derivative security position.

What is the exercise price of Marsha Fanucci’s GENB stock option grant?

The Form 4 states an exercise price of $0.00 per share for the stock option granted to Marsha Fanucci. This zero exercise price indicates the award functions as equity compensation, rather than a typical option requiring cash payment upon exercise.

When do the stock options granted to Marsha Fanucci by Generate Biomedicines vest?

The footnote explains that all 29,561 option shares vest in full on February 19, 2027. Vesting is subject to her continued service with Generate Biomedicines through that vesting date, meaning departure before then would affect the award.

Does the GENB Form 4 show direct or indirect ownership for this option grant?

The Form 4 classifies the ownership of this stock option as direct. The transaction is labeled with ownership code "D", and there is no indication in the footnotes that the option is held through a trust, LLC, or other indirect ownership structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 05:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fanucci Marsha

(Last) (First) (Middle)

GENERATE BIOMEDICINES, INC.

101 SOUTH STREET, SUITE 900

(Street)

SOMERVILLE MA 02143

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Generate Biomedicines, Inc. [ GENB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16	02/26/2026		A		29,561		(1)	02/25/2036	Common Stock	29,561	$0	29,561	D

Explanation of Responses:

1. The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

	/s/ Michael Wolf, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.